Ambrx Biopharma Cayman Inc

Ambrx Biopharma Cayman, Inc. operates as a biotech company. The Company focuses on creating next generation antibody drug conjugates (ADCs) for a variety of cancer indications, including our lead product candidate ARX517, a prostate-specific membrane antigen (PSMA) targeting ADC and ARX788. Ambrx Biopharma Cayman serves customers worldwide.